Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome

Rico, H.; Hernández, E. R.; Revilla, M.; Gómez-Castresana, F.

doi:10.1016/0169-6009(92)90883-f

Cited by 110 publications

(24 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After adjustment for differences in other risk factors, the relative risk of hip fracture was 0.69 (0.51-0.92) in women taking calcitonin. The effect on hip fractures increased significantly with an increase in the duration of exposure and calcitonin was equally effective in older and younger women [32], In a retrospective study, intramuscular administration of 100 IU/day of sal mon calcitonin given 10 days/month for 2 years to a group of postmenopausal women presenting with more than one vertebral crush fracture was associated with a significant reduction in new vertebral fracture rates compared to the incidence observed in a group of matched women receiv ing calcium only [33]. More recently, in a 2-year prospec tive study performed in elderly women with a low forearm bone mineral density treatment with nasal salmon calci tonin reduced the rates of fractures by two thirds com pared with calcium alone [28].…”

Section: Calcitoninmentioning

confidence: 99%

Treatment of Bone in Elderly Subjects: Calcium, Vitamin D, Fluor, Bisphosphonates, Calcitonin

Reginster

1995

Horm Res

View full text Add to dashboard Cite

Several approaches may be suggested for prevention or treatment of senile osteoporosis. In elderly patients, an association of calcium and vitamin D supplementation has been shown to reduce nonvertebral fractures up to 40% over an 18-month period. Calcitonin, given parenterally or nasally, may prevent further bone loss and has been reported to significantly decrease vertebral and hip fractures. This hormone also possesses an important analgesic effect. Fluoride salts are the most effective way to significantly increase bone mass, mainly at the trabecular site. The optimal doses and regimens remain to be clearly established. The use of new formulations like sodium monofluorophosphate are likely to facilitate the search of the optimal therapeutic window. Bisphosphonates are potent inhibitors of bone resorption. They have been shown to significantly increase trabecular bone mass without impairment of cortical bone. Their use may be associated with a significant decrease in vertebral fractures, mainly in patients with severe osteoporosis. The new, second and third generation of bisphosphonates (tiludronate, risedronate, alendronate) look extremely promising but their widespread use will only be possible after a confirmation of the absence of a deleterious effect on bone quality (alendronate) and after demonstration of a reduction in vertebral and/or hip fractures following a prolonged use.

show abstract

Section: Calcitoninmentioning

confidence: 99%

Treatment of Bone in Elderly Subjects: Calcium, Vitamin D, Fluor, Bisphosphonates, Calcitonin

Reginster

1995

Horm Res

View full text Add to dashboard Cite

show abstract

“…Calcitonins, which have not yet been truly validated by controlled studies in the prevention of vertebral fractures in spite of certain publications [14][15], are still widely prescribed as basic treatment (40%), sometimes in association with phosphorus.…”

Section: Discussionmentioning

confidence: 99%

Does the french general practitioner correctly investigate and treat osteoporosis?

Laroche

Mazières

1998

Clin Rheumatol

View full text Add to dashboard Cite

In our region, more than half the patients with osteoporosis are investigated and treated by general practitioners. We carried out two surveys to discover whether the diagnosis and treatment of osteoporosis were correctly carried out by general practitioners in the Midi-Pyrénées region. The first survey concerned 85 patients who had been diagnosed with osteoporosis by their general practitioner. These patients were being seen for the first time in a hospital or private practice setting by a rheumatologist who completed a questionnaire based solely on the history taken from the patient and the records in the patient's possession. For the second survey, 200 general practitioners who had referred patients to the rheumatology department were sent a questionnaire on their management of osteoporosis. Fifty-two physicians completed and returned the questionnaire. More than half the general practitioners started treatment of osteoporosis without fractures on the basis of standard spinal X-rays where the radiologist suggested bone mineral loss. The initial biological investigation was correctly carried out by only 6% of physicians. Treatment was correctly prescribed in only 34% of cases of osteoporosis with fractures, 50% of osteoporosis without fractures and 50% of senile cortical osteoporosis.

show abstract

“…25 (1993) 484-485 © Georg Thieme Verlag Stuttgart • New York bilization of bone mass to a significant increase of bone mineral density at both the trabecular and cortical level (Mazzuoli et al 1986;Overgaard et al 1989;Reginster, Denis, Albert, Deroisy, Lecart, Fontaine, Lembelin and Franchimont 1987;Szucs, Horvath, Kollin, Szathmari and Hollo 1992). Furthermore, recent studies performed using salmon calcitonin nasal spray showed a significant reduction in fracture rate in patients with established osteoporosis (Overgaard, Hansen, Jensen and Christiansen 1992;Rico, Hernandez, Revilla and Gomez-Castresana 1992). In previous studies we demonstrated that calcitonin therapy is particularly indicated in patients with high-turnover osteoporosis, in which a gain of bone mass in the axial skeleton and a slowing of bone loss in the appendicular bones have been observed (Civitelli et al 1988;Gennari, Agnusdei and Camporeale 1993).…”

Section: Calcitonin Bone Mineral Density Bone Turnover and Fracturementioning

confidence: 94%

Long Term Treatment With Calcitonin in Osteoporosis

Gennari¹,

Agnusdei²,

Camporeale³

1993

Horm Metab Res

View full text Add to dashboard Cite

Many studies have shown that calcitonin has beneficial effects on the clinical and biological disturbances of diseases characterized by an excessive bone remodelling. Several controlled clinical studies have shown that long-term calcitonin treatment, given by parenteral or intranasal routes, exerts a beneficial positive effect on bone mass and bone turnover in established postmenopausal osteoporosis. Calcitonin therapy is particularly indicated for patients with high turnover osteoporosis where results show a net gain of bone mineral in the axial skeleton and a slowing of bone loss in the appendicular bones. Recently, calcitonin was shown to induce a significant reduction in postmenopausal osteoporotic vertebral fractures. Due to receptor down-regulation a resistance to the hormone may occur after 12-18 months of continuous treatment. Reported results of long-term calcitonin treatment demonstrated that it is possible to delay or to avoid the "resistance" to calcitonin by the cyclical or discontinued administration of the hormone.

show abstract

Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome

Cited by 110 publications

References 28 publications

Treatment of Bone in Elderly Subjects: Calcium, Vitamin D, Fluor, Bisphosphonates, Calcitonin

Treatment of Bone in Elderly Subjects: Calcium, Vitamin D, Fluor, Bisphosphonates, Calcitonin

Does the french general practitioner correctly investigate and treat osteoporosis?

Long Term Treatment With Calcitonin in Osteoporosis

Contact Info

Product

Resources

About